Anna Berkenblit
advocateFemale0.0Global Dominance: 0.00%
Anna Berkenblit is the head of the Pancreatic Cancer Action Network, who praised the rapid approval of daraxonrasib, highlighting its potential to significantly change treatment outcomes for patients with pancreatic cancer.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Anna Berkenblit praised the rapid approval, stating that the drug could radically change the landscape.
Πειραματικό χάπι γεννά ελπίδες για έναν από τους πιο θανατηφόρους καρκίνουςKathimerini·
Greece· 2025-11-06
Greece· 2025-11-06
